Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherapy, and (223)Ra), most of these patients still succumb to prostate cancer. Recently, (177)lutetium prostate-specific membrane antigen radioligand therapy ((177)Lu-PSMA-RLT) has been increasingly used within compassionate use provisions in these patients in Germany and showed promising efficacy.
Establishment of the current position of (177)Lu-PSMA-RLT in mCRPC in 2017.
Presentation of the therapy landscape in mCRPC and the current challenges within treatment and survey of the available data on (177)Lu-PSMA-RLT after PubMed-based research.
In several larger retrospective studies, (177)Lu-PSMA-RLT seems to be an encouraging new option with the potential to extend overall survival while displaying a favorable toxicity profile.
Prospective trials are urgently needed to confirm these encouraging results found in retrospective analyses with (177)Lu-PSMA-RLT in the treatment of mCRPC.
Der Urologe. Ausg. A. 2017 Oct 06 [Epub ahead of print]
M Boegemann, A J Schrader, K Rahbar
Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland. ., Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1 GB A1, 48149, Münster, Deutschland., Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland.